Feature | August 19, 2013

Medtronic Submits Drug-Eluting Balloon for FDA Review

Vendor hopes for pre-market approval for novel peripheral angioplasty device in second half of 2015

August 19, 2013 — Medtronic Inc. announced the submission of its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon. Designed to treat atherosclerotic lesions in the superficial femoral artery (SFA), the novel angioplasty device remains investigational in the United States.

“Pending FDA approval, we remain on track to launch the IN.PACT Admiral drug-eluting balloon in the United States during the second half of calendar year 2015,” said Tony Semedo, president of Medtronic’s Endovascular Therapies business. “In the meantime, we will continue working with leading healthcare providers and researchers around the world to amass clinical and economic evidence to support the global adoption of this innovative medical technology as an important addition to the treatment options for peripheral artery disease in the lower extremities.”

The ongoing global clinical program of IN.PACT drug-eluting balloons for the treatment of peripheral artery disease (PAD) in the lower extremities includes 24 studies involving more than 4,200 patients at approximately 230 sites worldwide. A combination of physician-initiated and company-sponsored studies, the program will fully characterize the safety and efficacy of these combination devices in a variety of peripheral vascular beds, including below-the-knee arteries.

Medtronic’s PMA application for the IN.PACT Admiral drug-eluting balloon will include clinical data from the IN.PACT SFA I and SFA II pivotal studies, the IN.PACT SFA II pharmacokinetics (PK) study, and the IN.PACT Global study, which have enrolled a total of more than 1,000 patients to date.

IN.PACT drug-eluting balloons feature a proprietary coating called FreePac that is a formulation of the antiproliferative drug paclitaxel and the biocompatible excipient urea, which facilitates rapid absorption of the drug into the vessel wall.

Several IN.PACT drug-eluting balloons received CE mark in 2008 and 2009 and are available in many countries around the world. In the United States, the IN.PACT Admiral drug-eluting balloon is limited to investigational use, and, like all drug-eluting balloons, is not yet commercially available.

The treatment of PAD varies by stage of progression and other factors, with lifestyle modifications aimed at risk factor reduction recommended for all stages. Drug-eluting balloons represent a relatively recent addition to the procedural approaches, which also include atherectomy, balloon angioplasty and stenting. In cases involving especially long lesions, bypass surgery can create a new route for blood flow around the diseased artery.

For more information: www.medtronic.com

Related Content

The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons| November 02, 2017
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons| August 29, 2017
C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
Philips acquires purchases Spectranetics
Feature | Business| June 28, 2017
Philips Healthcare and Spectranetics Corp. announced they have entered into a definitive merger agreement for $2.05...
News | June 12, 2017
June 12, 2017 – Med Alliance announced completion on schedule of patient enrollment in the first-in-man (FIM) study o
Twelve-Month Data Positive for Ranger Paclitaxel-Coated Balloon Catheter
News | Drug-Eluting Balloons| April 26, 2017
Boston Scientific announced results from the RANGER SFA trial for the Ranger Paclitaxel-Coated PTA Balloon Catheter at...
Overlay Init